ROHTO PHARMACEUTICAL CO.,LTD. Toevoegen aan een lijst
|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 3.064 JPY | -0,49% |
|
+2,72% | +7,77% |
| 04/04 | Mitsui en Rohto kopen $594 mln Chinees geneesmiddelenbedrijf Eu Yan Sang | RE |
| 2023 | Japanse aandelen sluiten maandag marginaal hoger in aanloop naar ontmoeting Biden-Xi | MT |
Totale waarde
| Fiscaal tijdperk: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Marktkapitalisatie 1 | 323.906 | 337.648 | 336.849 | 421.488 | 631.946 | 699.017 | - | - |
| Bedrijfswaarde 1 | 291.219 | 299.636 | 291.984 | 370.080 | 563.688 | 624.947 | 603.761 | 581.147 |
| K/w-verhouding | 33 x | 21,9 x | 20,1 x | 20,1 x | 24 x | 22,5 x | 20,1 x | 18,1 x |
| Dividendrendement | 0,88% | 0,88% | 0,95% | 0,97% | 0,79% | 0,89% | 0,96% | 1,04% |
| Marktkapitalisatie/omzet | 1,76 x | 1,79 x | 1,86 x | 2,11 x | 2,65 x | 2,58 x | 2,38 x | 2,21 x |
| Bedrijfswaarde/omzet | 1,59 x | 1,59 x | 1,61 x | 1,85 x | 2,36 x | 2,31 x | 2,05 x | 1,83 x |
| Bedrijfswaarde/EBITDA | 10,7 x | 9,98 x | 9,82 x | 10 x | 13,5 x | 12,6 x | 11 x | 9,65 x |
| Bedrijfswaarde/FCF | 19,3 x | 25 x | 30,5 x | 34,1 x | 31,8 x | 23,3 x | 20,1 x | 17,1 x |
| FCF Yield | 5,19% | 4% | 3,28% | 2,93% | 3,15% | 4,29% | 4,97% | 5,84% |
| Price to Book | 2,48 x | 2,43 x | 2,17 x | 2,37 x | 3,02 x | 3,01 x | 2,66 x | 2,42 x |
| Aantal aandelen (in duizenden) | 227.942 | 228.140 | 228.140 | 228.140 | 228.139 | 228.139 | - | - |
| Referentieprijs 2 | 1.421 | 1.480 | 1.476 | 1.848 | 2.770 | 3.064 | 3.064 | 3.064 |
| Datum van publicatie | 10/05/19 | 12/05/20 | 12/05/21 | 12/05/22 | 12/05/23 | - | - | - |
1JPY in Miljoen2JPY
Geschatte gegevens
Evolutie van de resultatenrekening (Jaargegevens)
| Fiscaal tijdperk: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 183.582 | 188.327 | 181.287 | 199.646 | 238.664 | 271.112 | 293.962 | 316.875 |
| EBITDA 1 | 27.216 | 30.022 | 29.738 | 37.022 | 41.760 | 49.785 | 54.811 | 60.213 |
| Bedrijfsresultaat (EBIT) 1 | 20.812 | 23.085 | 22.990 | 29.349 | 33.959 | 41.062 | 46.038 | 51.262 |
| Operationele Marge | 11,34% | 12,26% | 12,68% | 14,7% | 14,23% | 15,15% | 15,66% | 16,18% |
| Resultaat voor belastingen (EBT) 1 | 16.300 | 21.730 | 23.006 | 27.953 | 34.290 | 41.673 | 47.307 | 53.397 |
| Nettowinst (verlies) 1 | 9.799 | 15.410 | 16.743 | 21.018 | 26.377 | 31.036 | 34.750 | 38.726 |
| Nettomarge | 5,34% | 8,18% | 9,24% | 10,53% | 11,05% | 11,45% | 11,82% | 12,22% |
| WPA 2 | 43,00 | 67,56 | 73,39 | 92,13 | 115,6 | 136,0 | 152,3 | 169,7 |
| Free Cash Flow 1 | 15.128 | 11.971 | 9.574 | 10.844 | 17.748 | 26.790 | 29.990 | 33.948 |
| FCF-marge | 8,24% | 6,36% | 5,28% | 5,43% | 7,44% | 9,88% | 10,2% | 10,71% |
| Kasstroomconversie (ebitda) | 55,58% | 39,87% | 32,19% | 29,29% | 42,5% | 53,81% | 54,72% | 56,38% |
| Kasstroomconversie (nettowinst) | 154,38% | 77,68% | 57,18% | 51,59% | 67,29% | 86,32% | 86,3% | 87,66% |
| Dividend per aandeel 2 | 12,50 | 13,00 | 14,00 | 18,00 | 22,00 | 27,14 | 29,29 | 31,86 |
| Datum van publicatie | 10/05/19 | 12/05/20 | 12/05/21 | 12/05/22 | 12/05/23 | - | - | - |
1JPY in Miljoen2JPY
Geschatte gegevens
Evolutie van de resultatenrekening (Kwartaalgegevens)
| Fiscaal tijdperk: March | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 | 2025 Q1 | 2025 Q2 | 2025 S1 | 2025 Q3 | 2025 Q4 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 90.428 | 97.899 | 83.004 | 98.283 | 48.704 | 91.019 | 53.003 | 55.624 | 108.627 | 52.255 | 58.058 | 110.313 | 65.950 | 62.401 | 61.171 | 66.698 | 127.869 | 73.294 | 71.304 | 145.100 | 67.450 | 73.250 | 140.100 | 80.700 | 75.100 | 154.400 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Bedrijfsresultaat (EBIT) 1 | 10.393 | 12.692 | 10.779 | 12.211 | 7.763 | 13.771 | 9.777 | 5.801 | 15.578 | 8.302 | 7.967 | 16.269 | 12.329 | 5.361 | 11.292 | 9.674 | 20.966 | 14.296 | 5.653 | 19.700 | 11.950 | 11.200 | 23.800 | 16.250 | 7.600 | 23.700 |
| Operationele Marge | 11,49% | 12,96% | 12,99% | 12,42% | 15,94% | 15,13% | 18,45% | 10,43% | 14,34% | 15,89% | 13,72% | 14,75% | 18,69% | 8,59% | 18,46% | 14,5% | 16,4% | 19,51% | 7,93% | 13,58% | 17,72% | 15,29% | 16,99% | 20,14% | 10,12% | 15,35% |
| Resultaat voor belastingen (EBT) | 10.478 | 11.252 | 9.050 | 13.956 | 7.429 | 13.840 | 9.709 | 4.404 | - | 9.655 | 8.155 | 17.810 | 11.717 | 4.763 | 12.242 | 10.302 | 22.544 | 14.026 | - | - | - | - | - | - | - | - |
| Nettowinst (verlies) 1 | 7.305 | 8.105 | 6.178 | 10.565 | 6.025 | 10.756 | 6.177 | 4.085 | 10.262 | 6.994 | 6.198 | 13.192 | 8.445 | 4.740 | 9.090 | 7.504 | 16.594 | 9.563 | 5.038 | - | - | - | - | - | - | - |
| Nettomarge | 8,08% | 8,28% | 7,44% | 10,75% | 12,37% | 11,82% | 11,65% | 7,34% | 9,45% | 13,38% | 10,68% | 11,96% | 12,81% | 7,6% | 14,86% | 11,25% | 12,98% | 13,05% | 7,07% | - | - | - | - | - | - | - |
| WPA 2 | 32,04 | - | 27,08 | - | 26,41 | 47,15 | 27,08 | 17,90 | - | 30,66 | 27,16 | 57,82 | 37,02 | - | 39,85 | 32,89 | 72,74 | 41,92 | 21,23 | - | 38,13 | 34,63 | - | 53,04 | - | - |
| Dividend per aandeel | 6,500 | - | 6,500 | - | - | 7,500 | - | - | - | - | - | 10,00 | - | - | - | 12,00 | 12,00 | - | - | - | - | - | - | - | - | - |
| Datum van publicatie | 13/11/19 | 12/05/20 | 12/11/20 | 12/05/21 | 11/11/21 | 11/11/21 | 10/02/22 | 12/05/22 | 12/05/22 | 9/08/22 | 10/11/22 | 10/11/22 | 13/02/23 | 12/05/23 | 9/08/23 | 10/11/23 | 10/11/23 | 9/02/24 | - | - | - | - | - | - | - | - |
1JPY in Miljoen2JPY
Geschatte gegevens
Balans
| Fiscaal tijdperk: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Nettoschuldpositie 1 | - | - | - | - | - | - | - | - |
| Nettokaspositie 1 | 32.687 | 38.012 | 44.865 | 51.408 | 68.258 | 74.070 | 95.256 | 117.870 |
| Hefboom (schuld/ebitda) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 15.128 | 11.971 | 9.574 | 10.844 | 17.748 | 26.790 | 29.990 | 33.948 |
| ROE (netto-inkomsten/eigen vermogen) | 7,6% | 11,4% | 11,7% | 12,6% | 13,6% | 14,2% | 14,2% | 14,2% |
| ROA (netto-inkomsten/totale activa) | 9,44% | 10,9% | 10,8% | 11,6% | 12,2% | 9,65% | 10,1% | 10,4% |
| Totale activa 1 | 103.773 | 141.070 | 154.437 | 180.817 | 216.658 | 321.619 | 345.771 | 372.368 |
| Nettoactief per aandeel 2 | 574,0 | 609,0 | 682,0 | 780,0 | 917,0 | 1.018 | 1.152 | 1.265 |
| Cashflow per aandeel | 70,00 | 94,10 | 101,0 | 124,0 | 148,0 | - | - | - |
| Capex 1 | 6.617 | 7.069 | 10.434 | 11.948 | 12.024 | 9.110 | 9.067 | 9.300 |
| Capex/omzet | 3,6% | 3,75% | 5,76% | 5,98% | 5,04% | 3,36% | 3,08% | 2,93% |
| Datum van publicatie | 10/05/19 | 12/05/20 | 12/05/21 | 12/05/22 | 12/05/23 | - | - | - |
1JPY in Miljoen2JPY
Geschatte gegevens
WPA & Dividend
Historische koers/winstverhouding
Evolutie van de historische prestaties
Historische marktkapitalisatie/EBITDA
Trading rating
Beleggingsrating
ESG Refinitiv
Verkoop
Koop
Gemiddeld advies
Kopen
Aantal analisten
8
Laatste slotkoers
3.064
JPY
Gemiddelde koersdoel
3.892
JPY
Spread / Gemiddelde doel
+27,04%
Herzieningen van WPA
| Vaira. 1 jan. | Kapi. | |
|---|---|---|
| +7,77% | 4,46 mld. | |
| +29,68% | 699 mld. | |
| +25,07% | 571 mld. | |
| -4,35% | 364 mld. | |
| +17,65% | 326 mld. | |
| +3,77% | 286 mld. | |
| +14,68% | 236 mld. | |
| +4,71% | 198 mld. | |
| -12,43% | 194 mld. | |
| -3,79% | 154 mld. |
- Beurs
- Aandelen
- Koers 4527
- Financiën Rohto Pharmaceutical Co.,Ltd.
